Correction: Kinetic change of serum carcinoembryonic antigen can early predict progression in patients with metastatic non-small cell lung cancer during maintenance therapy with bevacizumab plus pemetrexed

Nasha Zhang; Li Kong; Fang Shi; Wang Jing; Haiyong Wang; Ming Yang; Jinming Yu; Hui Zhu

doi:10.18632/oncotarget.23291

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Corrections:

Correction: Kinetic change of serum carcinoembryonic antigen can early predict progression in patients with metastatic non-small cell lung cancer during maintenance therapy with bevacizumab plus pemetrexed

PDF | How to cite

Oncotarget. 2017; 8:110732-110732. https://doi.org/10.18632/oncotarget.23291

Metrics: PDF 1417 views | ?

Nasha Zhang^1,2, Li Kong^2,3, Fang Shi^2,3, Wang Jing², Haiyong Wang^2,3, Ming Yang^2,3, Jinming Yu^2,3 and Hui Zhu^2,3

¹ Cheeloo College of Medicine, Shandong University, Jinan, China
² Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong Cancer Hospital Affliated to Shandong University, Jinan, China
³ Shandong Academy of Medical Sciences, Jinan, China

Published: December 15, 2017

This article has been corrected: the authors first and last names order was updated

Original article: Oncotarget. 2017; 8:74910-74916. DOI: https://doi.org/10.18632/oncotarget.20456.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 23291

Publication Alerts

Corrections:

Correction: Kinetic change of serum carcinoembryonic antigen can early predict progression in patients with metastatic non-small cell lung cancer during maintenance therapy with bevacizumab plus pemetrexed